Chaojie Zhu

Mr. Chaojie Zhu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
JMJunkai Ma
Junkai Ma
ZJZhiheng Ji
Zhiheng Ji
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, causing approximately 17.9 million deaths annually, an estimated 31% of all deaths, according to the WHO. CVDs are essentially rooted in atherosclerosis and are clinically classified into coronary heart disease, stroke and peripheral vascular disorders. Current clinical interventions include early diagnosis, the insertion of stents, and long-term preventive therapy. However, clinical diagnostic and therapeutic tools are subject to a number of limitations including, but not limited to, potential toxicity induced by contrast agents and unexpected bleeding caused by anti-platelet drugs. Nanomedicine has achieved great advancements in biomedical area. Among them, cell membrane coated nanoparticles, denoted as CMCNPs, have acquired enormous expectations due to their biomimetic properties. Such membrane coating technology not only helps avoid immune clearance, but also endows nanoparticles with diverse cellular and functional mimicry. In this review, we will describe the superiorities of CMCNPs in treating cardiovascular diseases and their potentials in optimizing current clinical managements.

6 March 2024 in Nature Materials
Verified
Journal Article
Closed access
PDF file
JSJiaqi Shi
Jiaqi Shi
WWWei Wu
Wei Wu
DCDong Chen
Dong Chen
ZLZiyan Liao
Ziyan Liao
TSTao Sheng
Tao Sheng
ZGZhen Gu
Zhen Gu

7 August 2023 in Accounts of Materials Research
Verified
Journal Article
Closed access
CZChaojie Zhu
Chaojie Zhu
JJJianping Jiang
Jianping Jiang
YJYingbo Jia
Yingbo Jia
Zhi Ping XuZhi Ping Xu
Zhi Ping Xu
Lingxiao ZhangLingxiao Zhang
Lingxiao Zhang

22 November 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
CLChao Liu
Chao Liu
QWQing Wu
Qing Wu
TSTao Sheng
Tao Sheng
RZRuyi Zhou
Ruyi Zhou
HLHongjun Li
Hongjun Li
The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells. Here, we developed a bacterial-based adjuvant approach that augments the efficacy of adoptive T-cell therapy for solid tumor treatment. Our study reveals that intratumor injection of E. coli MG1655 normalizes tumor vasculatures and reprograms tumor-associated macrophages into M1 phenotype that produce abundant CCL5, together facilitating tumor infiltration of adoptively transferred T cells. The depletion of tumor-associated macrophages or CCL5 neutralization in vivo leads to the significantly decreased solid tumor infiltration of adoptive T cells in the presence of bacteriotherapy. This combinatorial therapy, consisting of E. coli adjuvant and adoptive T-cell therapy, effectively eradicates early-stage melanoma and inhibits the progression of pancreatic tumors. Notably, this dual strategy also strengthened the distal tumor control capabilities of adoptive T-cell therapy through the induction of in situ tumor vaccination. This dual therapeutic approach involving bacterial therapy targeting the interior of solid tumors and adoptive T-cell therapy attacking the tumor periphery exhibits potent therapeutic efficacy in achieving the eradication of advanced-stage tumors, including melanoma and hepatocellular carcinoma, by converging attacks from both inside and outside the tumor tissues.

24 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
ZJZhiheng Ji
Zhiheng Ji
JMJunkai Ma
Junkai Ma
ZDZhijie Ding
Zhijie Ding
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.

5 January 2023 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
XSXinyuan Shen
Xinyuan Shen
CZChaojie Zhu
Chaojie Zhu
XLXutao Liu
Xutao Liu
HZHanqi Zheng
Hanqi Zheng
QWQing Wu
Qing Wu
HLHongjun Li
Hongjun Li
Engineered bacteria can be leveraged for in situ tumor vaccinations with their tumor-targeting ability and adjuvanticity. Engineering strategies like chemical modification, nanotechnology, and genetic engineering improve their safety and efficacy.